Basaglar ® (insulin glargine) injection

100 units/mL

This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.

BASAGLAR® (insulin glargine injection): Transitioning From Insulin Detemir

Based on analyses of trials, a dosage reduction may be warranted when transitioning from IDet to Basaglar.

Transitioning From Insulin Detemir to Basaglar

No dedicated trial has been conducted to investigate patients transitioning from IDet to Basaglar.

To compare insulin doses in patients treated with IGlar or IDet, Wallace et al conducted an analysis that included

  • 5 large RCTs in patients with T2DM, and

  • 2 large RCTs in patients with T1DM.1

To achieve similar glycemic control, patients treated with IDet required on average a 38% higher dose of insulin compared with patients treated with IGlar (Table 1).1

Dailey et al conducted a pooled analysis of 22 RCTs in patients with T2DM to compare insulin doses in patients treated with IGlar or IDet. To achieve a similar reduction in HbA1c levels, patients treated with IDet required a 31% higher mean insulin dose compared with patients treated with IGlar (Table 1).2

Table 1. Analysis of Doses in Patients Treated With Insulin Glargine or Insulin Detemir in Randomized Controlled Trials1,2



Patient Population

Dose of IGlar Compared With IDet for Similar HbA1c Reduction

Wallace, 2014

7 RCTsa

T1DM or T2DM

8.0%-77.2% (average 38%) higher IDet dose

Dailey, 2010b

22 RCTs


0.59 (0.07) units/kg for IDetc

0.45 (0.02) units/kg for IGlar

Abbreviations: HbA1c = glycated hemoglobin; IDet = insulin detemir; IGlar = insulin glargine; RCT = randomized controlled trial; T1DM = type 1 diabetes mellitus; T2DM = type 2 diabetes mellitus.

a Represents 5 RCTs in patients with T2DM and 2 RCTs in patients with T1DM.

b Data presented as mean (SE).

c Represents a 31% higher insulin dose vs IGlar.

Wallace et al concluded that since higher doses of IDet may be needed to obtain similar glycemic control, prescribers may consider a dosage reduction when transitioning from IDet to IGlar in order to reduce the risk of hypoglycemia that may result when using a unit-to-unit conversion.1

General Dosing Guidelines When Transitioning to Basaglar

If transitioning from a treatment regimen with an intermediate- or long-acting insulin, other than an IG-100 product, to a regimen with Basaglar,

  • a change in the dose of the basal insulin may be required, and

  • the amount and timing of shorter-acting insulins and doses of any antihyperglycemic medications may need to be adjusted.3

Enclosed Prescribing Information

BASAGLAR® (insulin glargine injection), for subcutaneous use, Lilly


The published references below are available by contacting 1-800-LillyRx (1-800-545-5979).

1. Wallace JP, Wallace JL, McFarland MS. Comparing dosing of basal insulin analogues detemir and glargine: is it really unit-per-unit and dose-per-dose? Ann Pharmacother. 2014;48(3):361‑368.

2. Dailey G, Admane K, Mercier F, Owens D. Relationship of insulin dose, A1c lowering, and weight in type 2 diabetes: comparing insulin glargine and insulin detemir. Diabetes Technol Ther. 2010;12(12):1019-1027.

3. Basaglar [package insert]. Indianapolis, IN: Eli Lilly and Company; 2019.


Basaglar = Basaglar® (insulin glargine injection) 100 units/mL

HbA1c = glycated hemoglobin

IDet = insulin detemir

IG-100 = insulin glargine 100 units/mL

IGlar = insulin glargine

RCT = randomized controlled trial

T1DM = type 1 diabetes mellitus

T2DM = type 2 diabetes mellitus

Date of Last Review: January 07, 2020

Contact Lilly

Call Us

If you need information about a Lilly product or want to report an Adverse Event or Product Complaint, you may call us.

Available Mon – Friday, 9am-7pm (EST), excluding holidays

Or you can

Chat with us

Chat with us

Submit a Request

Visit Us @LillyMedical